awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE
Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE
Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"
P2860
Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q54296806-CC05FA31-9AD8-41EB-99DD-26D7C6DA20CE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4ade382311426e766b3e6138b63c61189baa5c26
P2860
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.